Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

June 30, 2010

Study Completion Date

October 31, 2015

Conditions
Fertility PreservationAlkylating AgentsLymphoma
Interventions
DRUG

Triptorelin

Triptorelin: intramusculAR injection every 3 months

DRUG

Norethisterone acetate

5 mg/day per os until during chemotherapy

Trial Locations (15)

1000

Bordet, Brussels

1070

Erasme Hospital, Brussels

1090

AZ-VUB, Brussels

1200

St Luc University, Brussels

2060

Algemeen Ziekenhuis Stuivenberg, Antwerp

8000

AZ St Jan, Brugges

21034

CHU Dijon, Dijon

54511

CHU Nancy, Nancy

59037

CHRU Lille, Lille

75004

Hôpital Hotel Dieu, Paris

75475

St Louis Hospital, Paris

75571

CHU St Antoine, Paris

76038

Centre Henri Beckerel, Rouen

94010

Henry-Mondor Hospital, Paris-Creteil

1-20141

Instituto Europeo di oncologia, Milan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fonds National de la Recherche Scientifique

OTHER

collaborator

Ipsen

INDUSTRY

lead

Erasme University Hospital

OTHER